Table 2.
Treatment characteristics
| Prior therapy | Controls (N = 52) | Mut-positive (N = 26) | P-value |
|---|---|---|---|
| Platinum-based regimen—no. (%) | |||
| FOLFIRINOX | 39 (75) | 10 (38) | 0.0016 |
| FOLFOX | 11 (21) | 10 (38) | 0.1 |
| Gemcitabine cisplatin | 1 (2) | 6 (23) | 0.0021 |
| Gemcitabine cisplatin nab-paclitaxel | 1 (2) | 0 (0) | 0.476 |
| Line of therapy containing platinum—no. (%) | |||
| First | 35 (67) | 21 (81) | 0.21 |
| Second | 15 (29) | 4 (15) | 0.19 |
| Third | 2 (4) | 1 (4) | >0.9 |
FOLFIRINOX includes fluorouracil, leucovorin, irinotecan and oxaliplatin
FOLFOX includes fluorouracil, leucovorin and oxaliplatin
One patient in the mut-positive group received FOLFIRINOX followed by gemcitabine cisplatin; the change was made due to 5-FU induced hand-foot syndrome